Clinical Trial

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Completed Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to evaluate the comparability of efficacy, safety, and immunogenicity of RPH-002 and Erbitux® when administered in combination with docetaxel and cisplatin as first-line therapy in patients with advanced head and neck squamous cell carcinoma
Protocol Amendment History 1 change
critical Trial completed 2026-07-15
Trial Details
NCT Number NCT07435324
Lead Sponsor R-Pharm
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 161 participants
Start Date 2024-08-08
Primary Completion 2025-09-16 (estimated)
Study Completion 2026-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-14